Biohabit

About Us

Who we are

Biohabit is a medical technology start-up focused on revolutionizing heart failure diagnostics with our point of care NT-proCheck test.

What we do

Unlike traditional methods, our test uses oral fluid instead of blood, making the process faster, easier, and more comfortable for patients.

Why we do

Our mission is to make diagnostic tools more accessible to everyone, improving quality of life and saving lives by enabling the early detection of heart failure.

Support Our Cause

Currently, we are raising funds for a critical clinical study to advance NT-proCheck. If you believe in our mission and want to support bringing this life-saving technology to market, please consider donating through the link below. Every contribution brings us one step closer to saving lives, and we deeply appreciate your support.

Team

Dr Vlad Miscianinov
MBiolSci PhD

CEO

Vlad began his research career at the University of Sheffield, where he earned a Master of Biological Sciences degree in Genetics. He continued his academic journey in Edinburgh, pursuing his PhD in Cardiovascular Science at the University of Edinburgh Medical School. Throughout his doctoral studies, Vlad authored and co-authored multiple publications, including a manuscript on the role of microRNA in cardiovascular disease and regeneration, and filed a patent for a microRNA-based wound healing gene therapy. Following his PhD, Vlad accepted a postdoctoral research fellow position in Professor Andrew Baker’s lab, where he developed a novel lncRNA-based gene therapy approach to prevent vein graft failure in patients undergoing coronary artery bypass surgery. Throughout his academic career, Vlad developed a keen interest in business, which ultimately led him to establish Biohabit Ltd, where he currently serves as CEO and R&D Director.

Dr John D Hung
MBChB PhD MRCP(UK) FRCPE

Medical Director

John holds a Medical degree from the University of Liverpool, and he completed his General Cardiology training at Countess of Chester, Aintree, and Royal Liverpool Hospital. He subsequently pursued a PhD at the University of Edinburgh, where he investigated the role of lncRNA in human atherosclerosis. In parallel, John served as a Cardiology Research Fellow and studied atherosclerosis using MRI and intravascular imaging. John has co-authored 15 research publications, highlighting his commitment to the field. Currently, John serves as a Consultant Cardiologist in Interventional Cardiology at Liverpool Heart and Chest Hospital, where he was recently promoted. He also co-founded Biohabit Ltd and serves as the Medical Director, where he combines his medical practice with his passion for developing breakthrough solutions in the field of precision and personalised medicine.

Contact Us

We are actively seeking strategic partnerships and are open to licensing our patented diagnostic technology. For more information, please reach out to us at info@biohabit.co.uk